Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback.

Browman, George P.; Newman, Toni; Mohide, E. Ann; Graham, Ian; Levine, M N; Pritchard, Kathleen I.; Wk, Evans; Maroun, J A; Hodson, D. Ian; Carey, Margaret; Cowan, D. H.

doi:10.1200/jco.1998.16.3.1226

Cited by 95 publications

(60 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many guidelines exist to assist clinicians how to evaluate symptoms, who should be tested, and what tests to order (38)(39)(40)(41)(42)(43)(44). Conceptual tools for development of new guidelines (45) and processes to achieve consensus on guidelines have been described (46,47). Guidelines have been shown to improve structure and processes of care, but with much more modest effects on patient outcomes (48,49).…”

Section: From a Survivormentioning

confidence: 99%

The Interface of Primary and Oncology Specialty Care: From Symptoms to Diagnosis

Nekhlyudov

Latosinsky

2010

JNCI Monographs

View full text Add to dashboard Cite

Section: From a Survivormentioning

confidence: 99%

The Interface of Primary and Oncology Specialty Care: From Symptoms to Diagnosis

Nekhlyudov

Latosinsky

2010

JNCI Monographs

View full text Add to dashboard Cite

“…This recommendation report, produced by the Program in Evidence-Based Care (pebc) and approved by the Stem Cell Transplant Steering Committee of Cancer Care Ontario, was developed through a systematic review of the available evidence using the methods of the practice guidelines development cycle 2,3 . The pebc is editorially independent of the Ontario Ministry of Health and Long-Term Care.…”

Section: Methodsmentioning

confidence: 99%

Plerixafor for Autologous Stem-Cell Mobilization and Transplantation for Patients in Ontario

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The Program in Evidence-Based Care (pebc) at Cancer Care Ontario (cco) produces evidence-based and evidenceinformed guidance documents using the methods of the practice guidelines development cycle 6,7 . The process includes a systematic review, interpretation of the evidence by the Working Group, draft recommendations, internal review by content and methodology experts, and external review by Ontario clinicians and other stakeholders.…”

Section: Development Of Recommendationsmentioning

confidence: 99%

Systemic Therapy for Recurrent Epithelial Ovarian Cancer: A Clinical Practice Guideline

et al. 2017

View full text Add to dashboard Cite

Objective The purpose of this guideline is to recommend systemic therapy options for women with recurrent epithelial ovarian cancer, including fallopian tube and primary peritoneal cancers. Methods This document updates the recommendations published in the 2011 Optimal Chemotherapy forRecurrent Ovarian Cancer guideline from Cancer Care Ontario. Draft recommendations were formulated based on evidence obtained through a systematic review of phase ii and iii randomized controlled trials (rcts). The draft recommendations underwent internal review by clinical and methodology experts, and external review by clinical practitioners through a survey assessing the clinical relevance and overall quality of the guideline. Feedback from the internal and external reviews was integrated into the clinical practice guideline. ResultsThe primary literature search yielded thirty-six primary research papers representing thirty rcts that met the eligibility criteria. The guideline provides recommendations for patients with serous tumour histologies and with recurrent, platinum-resistant, and platinum-sensitive ovarian cancer. ConclusionsThe body of evidence from trials that included olaparib and bevacizumab consistently shows a benefit in progression-free survival (pfs) without a corresponding benefit in overall survival (os). The Working Group for this guideline designated pfs, which is associated with symptom control, as a critical outcome. A finding of net benefit can therefore be concluded based on significant differences in pfs. However, that benefit is not without identified harms. Given the identified harms, patient involvement in the decision-making process must take into consideration the side effect profiles of olaparib and bevacizumab within the context of improved pfs but minimal change in os.

show abstract

Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback.

Cited by 95 publications

References 0 publications

The Interface of Primary and Oncology Specialty Care: From Symptoms to Diagnosis

The Interface of Primary and Oncology Specialty Care: From Symptoms to Diagnosis

Plerixafor for Autologous Stem-Cell Mobilization and Transplantation for Patients in Ontario

Systemic Therapy for Recurrent Epithelial Ovarian Cancer: A Clinical Practice Guideline

Contact Info

Product

Resources

About